From: Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabetics
C | S + M | G + M | D + M | |
---|---|---|---|---|
Participants | 20 | 21 | 20 | 19 |
Ratio male/female | 12/8 | 16/5 | 15/5 | 11/8 |
Age [a] | 65 ± 1.33 | 64 ± 1.5 | 65 ± 1.58 | 62 ± 1.92 |
Duration of diabetes [a] | - | 7.9 ± 0.9 | 8.7 ± 1.3 | 6.8 ± 0.9 |
BMI | 27.1 ± 3.5 | 31.6 ± 2.9 | 30.8 ± 2.9 | 30.2 ± 3.3 |
HbA1c | 5.6 ± 0.3 | 7.0 ± 0.5 | 7.2 ± 0.2 | 6.6 ± 0.4 |
Basal glucose [mg/dl] | 100.1 ± 1.5 | 148.0 ± 3.9*** | 146.0 ± 5.1*** | 144.3 ± 5.1*** |
Basal insulin [pmol/l] | 9.02 ± 0.87 | 17.23 ± 1.63*** | 10.64 ± 1.59°° | 11.70 ± 0.90° |
Basal proinsulin [pmol/l] | 5.26 ± 0.39 | 16.37 ± 1.45*** | 9.378 ± 0.97*/°°° | 6.878 ± 0.49°°° |